JRF Level, Research Assistant Openings in Arya Group

DR. REDDY’S  

INSTITUTE OF LIFE SCIENCES 

December 20, 2017

JRF Level, Research Assistant Openings in Arya Group

Projects In-Charge: Prabhat Arya, PhD

Distinguished Research Professor in Chemistry and Chemical Biology

Dept of Organic and Medicinal Chemistry 

Dr. Reddy's Institute of Life Sciences

University of Hyderabad Campus

E mail: prabhata@drils.org 

Group Website: www.prabhatarya.org

Job Description:Aiming to fill a position at the JRF, Research Assistant level with MSc (Organic Chemistry /Pharmacy/Medicinal Chemistry).  The positions involve working on multi-steps, Stereoselective Organic Synthesis projects.  A good knowledge of modern organic synthesis is desirable. The candidate is expected to work on a collaborative, industrial sponsored project that aims a developing small molecule approaches to trans-differentiation of stem cells to neurons with potential applications to neurological disorders, such as Alzheimer's and Parkinson's.  The progress of the project will be strictly monitored at regular intervals to meeting the synthesis demands of this project.    

Period and start time: The initial appointment will be made for one year only. Tentative start

date: January 15 th , 2018 

Salary and benefits: As per JRF DST SERB guidelines. 

Interested eligible candidates can send their CV by e-mail to hr@drils.org by January 5, 2018

with subject line DRILS/JRF in Arya Group/Chemistry/2017. 

Please note that the appointment is purely temporary. Tentative dates for interview:  

January 8 th & 9 th , 2018.  No TA/DA will be paid for attending the interview. 

Punjab Parliamentarian Dr Gandhi seeks PM's intervention to regulate private healthcare cost

Joe C Mathew | New Delhi, Thursday, December 21, 2017 | 22:35 IST

Dharam Vira Gandhi, a parliamentarian from Punjab and a qualified medical practitioner, has sought the urgent intervention of the Prime Minister to ensure affordable healthcare to all citizens.

                                                                               

Punjab Parliamentarian Dr. Gandhi seeks PM's intervention to regulate private health care cost

The debate over whether or not the government needs to regulate private healthcare industry has reached Prime Minister Narendra Modi's doorsteps.

Dharam Vira Gandhi, a parliamentarian from Punjab and a qualified medical practitioner, has sought the urgent intervention of the Prime Minister to ensure affordable healthcare to all citizens.

In a letter to the PM with copies to the ministers of health and chemicals and petrochemicals, Gandhi wants the National Pharmaceutical Pricing Authority (NPPA) to be asked to take necessary steps to expand the list of medical devices under price control. He wants all medical devices to be brought under the definition of 'drugs' to make this happen. Gandhi also wanted the government to take necessary measures to control the prices of diagnostics and other investigations and impose price control on healthcare charges.

"Even though 'health' is a state subject, the concurrent list provides the jurisdiction to the Union government to introduce a regulatory framework to impose price control on health charges", the letter stated.

Gandhi alleged that private sector hospitals are charging exorbitant prices for providing healthcare. "Your government's vision to enhance the limit of Rashtriya Swasthya Bhima Yojana (RSBY) from RS 30,000 to Rs 100,000 have not reduced the financial burden of healthcare. There have been reports that private hospitals are using the government's health scheme to attract patients and then charging hefty fees by offering treatments not listed under RSBY. Furthermore, these schemes cover only people below poverty line, while the middle class is left with no option", he stated. 

Referring to the latest Central Bureau of Health Intelligence report, he states that 24.9 percent of Indian families is borrowing money to pay hospitalization costs.

Via Internet

India developing bulk drugs to reduce import dependence

By ,PTI | Dec 20, 2017, 04.51PM IST

India is in the process of developing a range of bulk drugs to reduce import dependence, especially from China, a top government official said today.

  

Although a large quantity of bulk drugs is imported from China, India has enough capacity for producing active pharmaceutical ingredients (API), Drug Controller General of India (DCGI) G N Singh told PTI on the sidelines of a CII event here.

"We are exporting to most of the developed markets including EU, US, and Japan so there is capacity, barring some of the molecules, where we are working, so that (import) dependency may also be curtailed. So, in due course of time that threat would not be there," he said.

India's bulk drug imports from top five countries stood at Rs 18,372.54 crore in 2016-17 with China accounting for 66 percent.

The country's import of APIs from China stood at Rs 12,254.97 crore in 2016-17, while that from the US was at Rs 820.18 crore.

 Singh said India has both capacity and capability to produce APIs although production of some of the bulk drugs was curtailed, driven by market dynamics.

"If need arises, the industry, the regulator, the scientific fraternity and the government are ready to meet the challenges," Singh said.

The regulator is constantly engaged with the industry on ways to address the issue, he added.

"It is an issue but not something, which cannot be solved," Singh said.

 On the challenges being faced by Indian pharmaceutical industry in terms of scrutiny by regulators from across the world, Singh said: "It is good. When you are growing, you should be ready for scrutiny and when other regulators are coming it gives the opportunity to address our weakness and convert it into strength."

The industry should take it as an opportunity, he added.

Via Internet

Liberate pharmacy education from dual control: Pharmaceutical Congress

ANI | Updated: Dec 24, 2017 19:38 IST

Chandigarh [India], Dec.24 (ANI): Arguing that pharmacy education courses are not technical programmes, the 69th Indian Pharmaceutical Congress (IPC) on Sunday passed a resolution that called on the Central Government to liberate all pharmacy courses from dual control of two agencies, the Pharmacy Council of India (PCI) and the All India Council for Technical Education (AICTE).

On the concluding day of the three day conference held here, Dr. Shailendra Saraf, Chairman, Local Organising Committee, said "the IPC issue of dual control of pharmacy education in India by Pharmacy Council of India (PCI) and All India Council for Technical Education (AICTE) has been affecting quality and prospects of pharmacy professionals for some time now. No initiative has been taken by the Central Government to sort out this issue even after repeated representations by the PCI and pharmacy professionals in the past. The PCI made an appeal to all the pharmaceutical associations, pharmacy professionals and new graduates to come together on one platform to press for a single regulating body for the pharmacy education in the country. Nothing much happened even after that appeal".

"The Indian Pharma Congress is upset mainly because the AICTE is also sanctioning new pharmacy colleges and conducting periodical inspections of these institutions without the knowledge of PCI. In view of this, there is confusion existing among pharmacy colleges, students and the common man as to which authority is actually responsible to ensure standards for pharmacy education and the profession. Now, the Pharmaceutical Congress has brought in a resolution urging the central government to do away with the AICTE control on pharmacy courses in the country".

Contrary to the cases of medical, nursing and dental educational courses, pharmacy education, which is also part of the healthcare system, comes under the regulatory purview of the technical education regulator, All India Council for Technical Education (AICTE). Along with statutory powers to regulate the educational programmes of engineering, technology, architecture, town planning, management, applied arts and crafts, hotel management and catering technology, the AICTE has been given the power to regulate the standards of degree and post graduate programmes in pharmacy conducted by academic institutions affiliated to various universities.

Dr. Saraf said that "under Pharmacy Act 1948, the Pharmacy Council of India (PCI) has the statutory power to control the pharmacy education and the institutions for approval for registration. It performs its duty well, and its advocacy as a single regulatory authority like Medical Council of India, Nursing Council of India and Dental Council of India, needs to be accepted and legally endorsed."

Dr.Dhirender Kaushik, Organising Secretary, LOC, PCI 2017 said, "The dual control over pharmacy education by AICTE and PCI creates hindrance for maintaining quality education all over India. Pharmacy education in the country needs to be improved much as per global standards. So, AICTE's interference in the management of pharmacy education should be done away with for the greater interest of the profession. For this, the Central Government's attention is required for suitable amendments in the act eventually to liberate the courses from the clutches of dual control."

On the concluding day, the Pharma Congress adopted some crucial issues in their resolution related to improvement and strengthening of pharmaceutical industry and overall profession of the country. One other resolution adopted related to the bulk import of active pharmaceutical ingredients (APIs), pharma raw materials required for drug formulations.

APIs and intermediates are key raw materials to manufacture pharmaceutical formulations such as tablets, capsules, syrups, etc. The pharma industry and the policy makers have raised concerns over India's rising dependence on imports from China for many APIs that go into the making of a number of essential drugs.

"India may have emerged as a key supplier of generic and affordable medicine for the world market, its overwhelming dependence on China for crucial raw materials, such as active pharmaceutical ingredients (APIs) and intermediates, to the extent of over 75 per cent of the requirement, has emerged as a main worrying area," said Dr. Kaushik

Apart from above issues the Congress has urged Union government to put in place an effective mechanism for the enforcement of safe drug through pharmacists only by making amendments in the Drug & Cosmetics Act 1948.

Over 10,000 delegates from India and abroad have assembled here to participate in the Congress making it a mega event for the pharmaceutical industry. The Indian Pharmaceutical Congress is a national annual event of pharmacist from all walks of pharmacy profession assembled to deliberate various issues relating to industry, regulatory, academia, hospitals and community pharmacy and to evolve collective wisdom for formulating newer policies for the country in the relevant fields and for the betterment of mankind.

The 69th IPC was held at the Chitkara University between December 22 and December 24 and was hosted by Association of Pharmaceuticals Teachers of India (APTI) and the Indian Pharmaceutical Congress Association (IPCA).

The theme "Skill and will to make and serve the quality pill" envisaged how a pharmacist can play a leading role in realizing the vision of a healthy India and stimulate thought processes accordingly. (ANI)

Via ANINEWS

Government of Assam Vacancy of Pharmacist: Permanent Jobs

Office of director of health services, Assam

Online application are invited for the following posts in 34 nos. of newly created Model Hospitals of the state under the establishment of the Directorate of Health Services, Assam. Form are available on the website of DHS Assam www.dhs.assam.gov.in from 16.12.2017-30.12.2017


For more details click here

Opportunity for Pharmacists (21 posts) in BSF - Detail advertisement

The Border Security Force (BSF) is a Border Guarding Force of India. Established on December 1, 1965, it is a paramilitary force charged with guarding India's land border during peace time and preventing transnational crime. It is a Union Government Agency under the administrative control of Ministry of Home Affairs.It is one of many law enforcement agency of India.It currently stands as the world's largest border guarding force.

Post : ASI (Pharmacist- Qualified) (Group-C Post)

No of Posts : 

21(UR-12, SC-03, ST-05, OBC-01)

Age : 18-25 years

Pay Band and Grade Pay : 
Band Pav Rs. 5200- 20200/- & Grade Pav- 2800/- (Pre revised)

Education Qualification
(i)10+2 or equivalent
(ii)  Degree or Diploma in Pharmacy from any recognized Institution of the Central or State Government for which the period of Training in two years followed by an internship of which the practical training shall not be less than five hundred hours spread over a period of not less than three months.
Provided that not less than two hundred and fifty hours are devoted to actual dispensing of prescriptions.
(iii) Possessing the qualifications under Section 31 & 32 of the Pharmacy Act, 1948 and registered under Section 33 of the said Act.

PROCESS OF CERTIFICATION AND FORMAT OF CERTIFICATES: 
Candidates who wish to be considered against vacancies reserved/or seek age- relaxation must submit requisite certificate from the competent authority, in the prescribed format when such certificate are sought by the concerned selection board at the time of Documentation. Otherwise, their claim for SC/ST/OBC/Ex- Servicemen status will not be entertained and their candidature/applications will be considered under General (UR) category. The formats of the certificates are Annexed. Certificates obtained in any other format will not be accepted. Candidates claiming OBC status may note that certificate on creamy layer status should have been obtained within three year before the closing date of application forms in the prescribed format only. Certificates issued up to the last tier of examination i.e. MET will also be accepted by the Selection Board

NOTE: Candidates are warned that they will be permanently debarred from the examination conducted by the BSF in case they fraudulently claim SC/ST/OBC/ Ex-S Status

PHYSICAL STANDARDS
Height
Male - 165 Cms
Female -150 Cms

Chest
Unexnanded Male -  76 Cms
Male - Expanded : 81 Cms
Female - Not Applicable

MEDICAL STANDARD
(i) Should be medically fit in all respects as per revised uniform medical guidelines issued by MHA vide UO No. A. VI-l/2014-Rectt(SSB) dated20/05/2015. Vision - Minimum near vision should be N6 & N9 and distant vision should be 6/6 and 6/9 of both eyes. Visual correction of any kind is not permitted (i.e. without wearing glasses).

(ii) Must pass CP III by ISIHARA colour vision test. Must not have knock- knees, flat feet or squint in eyes. Must not have any defect or deformity which likely to interfere with the efficient performance of the duties.

(iii) Weight - Corresponding to height and age.

Note
(i) Any candidate with a small engraving/tattoo of name or religious symbol on the inner face of the arms or hands is permitted for enrolment.
(ii) Candidates having permanent tattoo on any other part of the body be debarred for the recruitment.

DISQUALIFICATION
(i) No person
(a) Who has entered into or contracted a marriage with a person having spouse living. Or

(b) Who having a spouse living, has entered into or contracted a marriage with another person.
Shall be eligible for appointment to the Force, provided that the Central Government may, if satisfied that such marriage is permissible under the Personal law applicable to such person and the other party to the marriage and there are other grounds for so doing, exempt any person from the operation of this rule.
(ii) Conviction by any Court of Law.

(iii) Dismissal from Government Service.

(iv) Termination from BSF during probation.

For more details

No major impact on prices of Essential Drugs post introduction of GST

Government ensuring Essential drugs are available to public at reduced prices

Minister of State for Road Transport & Highways, Shipping and Chemicals & Fertilizers, Shri Mansukh L. Mandaviya, in a written reply to a question in Rajya Sabha today, informed that the Government has analyzed the impact of Goods and Services Tax (GST) on prices of the formulations and it is noticed that that there will be almost no impact on the prices of non-scheduled formulations which account for nearly 80% of the total pharmaceuticals sector.

In respect of Scheduled formulations, there is no impact on the prices of about 4% formulations, which mainly include formulations related to Immunization Program, Anti-cancer, Oral rehydration salts, Contraceptives etc. In most of the remaining formulations, which account for nearly 16% of total pharmaceutical sector, there is an increase in the prices to the extent of nearly 2.30%, the Minister informed.

Shri Mandaviya stated that the Government has fixed the ceiling prices of 851 formulations/ (packs) included in Revised Schedule - I of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The details have been uploaded on National Pharmaceutical Pricing Authority(NPPA)’s website www.nppaindia.nic.in. The slab-wise reduction in the prices under National List of Essential Medicines, 2015 (NLEM 2015) is as given below:

Slab-wise  Percentage reduction with respect to Maximum Price	No. of formulations
0<= 5%	234
5<=10%	134
10<=15%	98
15<=20%	98
20<=25%	93
25<=30%	65
30<=35%	46
35<=40%	24
Above 40%	59
Total formulations in NLEM 2015	851

Describing the measures taken to prevent overcharging of medicines, Shri Mandaviya stated that NPPA is effectively monitoring the prices of scheduled as well as non-scheduled medicines under DPCO, 2013 so that these formulations are available to public at ceiling prices notified and increase in price is limited to the provisions of DPCO, 2013. It takes action against companies found overcharging the consumers based on the references received from the State Drugs Controllers/ individuals, samples purchased from the open market, reports from market based data and complaints reported through the grievance redressal websites - ‘Pharma Jan Samadhan’ and‘Centralized Public Grievance Redress and Monitoring System (CPGRAMS)’. The monitoring of increase in the price of formulations beyond the permissible limit is also done on the basis of market data submitted by All Indian Origin Chemists & Distributors Limited(AIOCD) (Pharma Trac Data) and individual complaints received, the Minister added.

Further, the production and availability of medicines is also regularly monitored by the NPPA mainly through Drugs Control Administration of State Governments. Whenever shortage is reported by the State Drug Controllers or when the matter comes to the notice of NPPA, remedial steps are taken for ensuring availability of drugs by impressing upon manufacturers to rush the stocks to the places of shortage, Shri Mandaviya informed.

via

Press Information Bureau 
Government of India
Ministry of Chemicals and Fertilizers

for more details click here